Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability.

Crystal L Smith^1,2,3, Abigail Keever^1,2,3, Theresa Bowden^2,3,4, Katie Olson⁵, Nicole Rodin^2,3,4, Michael G McDonell^1,3, John M Roll^1,3, Gillian Smoody², Jeff LeBrun⁶, Andre Qc Miguel^1,2,3, Sterling M McPherson^1,2,3

¹Department of Community and Behavioral Health, Elson S Floyd College of Medicine, Washington State University, Spokane, WA, United States.

²Analytics and PsychoPharmacology Laboratory, Washington State University, Spokane, WA, United States.

³Program of Excellence in Addictions Research, Washington State University, Spokane, WA, United States.

⁴College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.

⁵Ideal Option, Spokane, WA, United States.

⁶Optimize Health, Seattle, WA, United States.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Opioid use disorders impact the health and well-being of millions of Americans. Buprenorphine and naloxone (BUP and NAL) can reduce opioid overdose deaths, decrease misuse, and improve quality of life. Unfortunately, poor medication adherence is a primary barrier to the long-term efficacy of BUP and NAL. OBJECTIVE: We aimed to examine patient feedback on current and potential features…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.